Mechanism of Gamma Oscillation Synchronization in the Prefrontal-hippocampal Circuit for Memory Dysfunction in Patients With White Matter Lesions of Cerebral Small Vessel Disease
Recruiting now
Conditions studied: Vascular Cognitive Impairment, White Matter Lesions, Gamma Oscillation
In brief
The mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease is still unclear. The disrupted synchronization of gamma oscillations in the prefrontal-hippocampal circuit is a potential key mechanism. Our study has demonstrated that white matter lesions lead to demyelination of the connection tracts between the prefrontal lobe and hippocampus, which is closely related to memory dysfunction. However, further studies are required to explore if these microstructural changes in white matter tracts influence memory function by affecting gamma oscillations. Thus, this project will use the previously established episodic memory task and event-related potential to determine the changes in gamma oscillations in the prefrontal-hippocampal circuit and the effects on memory encoding and retrieval. Combining multimodal imaging, we will explore the mediating role of white matter microstructure damage, and establish a machine learning prediction model for memory impairment. In addition, transcranial alternation current stimulation (tACS) will be used to investigate the mechanisms of memory improvement by regulating the prefrontal-hippocampal gamma oscillations. This project will clarify the neural oscillation mechanism underlying memory impairment caused by white matter lesions of cerebral small vessel disease, with the expectation of providing new predictive indicators and interventions.
Key facts
- Study ID
- NCT07042633
- Run by
- Xuanwu Hospital, Beijing
- People needed
- 150
- Starts
- 2024-03-07
- Expected to finish
- 2027-12-31
- Last updated by the study team
- 2025-06-29
Who can join
Age: 55 and older, up to 75. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- - Individuals with cerebral small vessel disease, normal cognition or mild cognitive impairment subjects;
- Participants with complete demographic data, neuropsychiatric scale assessments, imaging data, and EEG data.
You may not qualify if…
- Severe aphasia, physical disability, or other conditions preventing completion of neuropsychological assessments;
- History of cerebrovascular stroke with documented neurological deficits during onset and corresponding lesions on neuroimaging;
- Neurological disorders that may cause cognitive impairment, including alcohol abuse, drug addiction, traumatic brain injury, epilepsy, encephalitis, or normal-pressure hydrocephalus;
- Systemic diseases potentially contributing to mild cognitive impairment (e.g., hepatic/renal insufficiency, endocrine disorders, vitamin deficiencies);
- Current diagnosis of major depressive disorder or psychiatric disorders.
Where it is running
- Xuanwu Hospital Capital Medical University — Beijing, Beijing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.